2-MTHβC |
2-Methyl-1,2,3,4-tetrahydro-beta-carboline |
4-AcO-DALT |
4-Acetoxy-N, N-diallyltryptamine |
4-AcO-DET |
4-Acetoxy-N,N-diethyltryptamine |
4-AcO-DiPT |
4-Acetoxy-N, N- diisopropyltryptamine |
4-AcO-DMT |
4-Acetoxy-N,N-dimethyltryptamine |
4-AcO-DPT |
4-Acetoxy-N, N-dipropyltryptamine |
4-AcO-MET |
4-Acetoxy-N-methyl-N-ethyltryptamine |
4-HIAA |
4-Hydroxyindole acetic acid |
4-MeO-DMT |
4-Methoxy-N,N-dimethyltryptamine |
4-MeO-MiPT |
4-Methoxy-N-methyl-N-isopropyltryptamine |
4-OH-DET |
4-Hydroxy-diethyl-tryptamine |
4-OH-DMT |
4-Hydroxy-NN-dimethyltryptamine |
4-OH-DPT |
4-Hydroxy-N,N-dipropyltryptamine |
4-OH-MET |
4-Hydroxy-N-methyl-N-ethyltriptamine |
4-OH-MiPT |
4-Hydroxy-N-methyl-N-isopropyltryptamine |
4-OH-MPT |
4-Hydroxy-N-methyl-N-propyltryptamine |
4-OH-pyr-T |
4-Hydroxy-N,N-tetramethylenetryptamine |
5-HT |
5-Hydroxytryptamine |
5-MeO-DALT |
5-Methoxy-N,N-diallyltryptamine |
5-MeO-DET |
5-Methoxy-N,N-diethyltryptamine |
5-MeO-DiPT |
5-Methoxy-diisopropyltryptamine |
5-MeO-DMT |
5-Methoxy-N,N-dimethyltryptamine |
5-MeO-DPT |
5-Methoxy-N, N-dipropyltryptamine |
5-MeO-MET |
5-Methoxy-N-methyl-N-ethyltryptamine |
5-MeO-MiPT |
5-Methoxy-N-methyl-N-isopropyltryptamine |
5-MeO-MiPT-N-oxide |
5-Methoxy-N-methyl-N-isopropyltrypt-amine-N-oxide |
5-MeO-NiPT |
5-Methoxy-N-isopropyltryptamine |
5-MeO-TMT |
5-Methoxy-N,N-trimethyltryptamine |
5-MeO-α-MT |
5-Methoxy-alpha-methyltryptamine |
5-OH-DiPT |
5-Hydroxy-N,N-diisopropyltryptamine |
5-OH-DMT |
5-Hydroxy-N,N-dimethyltryptamine |
5-OH-MiPT |
5-Hydroxy-N-methyl-N-isopropyltryptamine |
CNS |
Central nervous system |
DBS |
Dried blood spots |
DDA |
Data dependent acquisition |
DEA |
Drug Enforcement Administration |
DET |
N,N-diethyltryptamine |
DiPT |
N,N-diisopropyltryptamine |
DLLME |
Dispersive liquid-liquid microextraction |
DMT |
N,N-dimethyltryptamine |
DMT-NO |
Dimethyltryptamine-N-oxide |
DPT |
N,N-dipropyltryptamine |
ED |
Emergency department |
EMCDDA |
European Monitoring Centre for Drugs and Drug Addiction |
FDA |
Food and Drug Administration |
GC |
Gas chromatography |
GC-EI-TOF |
Gas chromatography time-of-flight detection with electron impact ionization |
GC-MS |
Gas chromatography-mass spectrometry |
GDS |
Global Drug Survey |
HPLC |
High-performance liquid chromatography |
HPLC-MS |
High-performance liquid chromatography coupled with mass spectrometry |
IAA |
Indole-3-Acetic Acid |
IM |
Intramuscular |
IV |
Intravenous |
LC |
Liquid chromatography |
LC–HRMS/MS |
Liquid chromatography–high-resolution mass spectrometry |
LC-MS/MS |
Liquid chromatography coupled with mass spectrometry in |
LLE |
Liquid-liquid extraction |
LOD |
Limit of detection |
LSD |
Lysergic acid diethylamide |
MAO |
Monoamine oxidase |
MAOI |
Monoamine oxidase inhibitor |
MDMA |
3,4-Methylenedioxymethamphetamine |
MET |
N-methyl-N-ethyltryptamine |
MRM |
Multiple reaction monitoring |
NMT |
N-methyltryptamine |
NPS |
New psychoactive substances |
OH-5-MeO- MiPT |
hydroxy-5-methoxy-N-methyl-N-isopropyl-tryptamine |
PDA |
Photodiode array acquisition |
SIM |
Single ion monitoring |
SPE |
Solid phase extraction |
STAI |
Speilberg State-Trait Anxiety Inventory |
TOF |
Time of flight |
UHPLC-HRMS/MS |
Ultra-performance liquid chromatography-high resolution mass spectrometry |
UNODC |
United Nations Office on Drugs and Crime |
WHO |
World Health Organization |
α-ET |
Alpha-ethyltryptamine |
α-MT |
Alpha-methyltryptamine |